Exogenous sex hormones, menstrual and reproductive history, and risk of non-melanoma skin cancer among women: a systematic literature review and meta-analysis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 04 2021
Historique:
received: 24 08 2020
accepted: 30 03 2021
entrez: 20 4 2021
pubmed: 21 4 2021
medline: 11 11 2021
Statut: epublish

Résumé

Non-melanoma skin cancers (NMSC) are more frequent among men, but women (especially those aged < 40 years) have experienced steeper growth in their incidence rates in recent years. Hormonal factors were hypothesized to be playing a role in modulating NMSC risk, but the studies published to date provided conflicting results. We systematically reviewed and meta-analysed the studies focusing on the association between hormone-related characteristics (use of exogenous sex hormones, and aspects of menstrual and reproductive history) and the risk of NMSC among women. We included observational and experimental studies published in PubMed and EMBASE until February 2020. We calculated summary relative risk (SRR) and 95% confidence intervals (CI) by applying random effects models with maximum likelihood estimation, and used the I

Identifiants

pubmed: 33875740
doi: 10.1038/s41598-021-88077-y
pii: 10.1038/s41598-021-88077-y
pmc: PMC8056000
doi:

Substances chimiques

Gonadal Steroid Hormones 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

8524

Références

J Invest Dermatol. 2014 Jan;134(1):43-50
pubmed: 23877569
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Clin Oncol. 2015 Dec 1;33(34):4058-65
pubmed: 26527779
Cancer Res. 1994 Jan 15;54(2):437-40
pubmed: 8275480
Dtsch Arztebl Int. 2012 Oct;109(43):715-20
pubmed: 23181135
Carcinogenesis. 2009 Feb;30(2):340-7
pubmed: 18952596
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2942-9
pubmed: 20861398
Br J Cancer. 2018 Jan;118(2):294-298
pubmed: 29073637
Carcinogenesis. 2008 Oct;29(10):1950-4
pubmed: 18641401
Int J Cancer. 2016 Jul 15;139(2):300-9
pubmed: 26941014
Pharmacoeconomics. 2011 Oct;29(10):863-74
pubmed: 21846158
JAMA. 2005 Aug 10;294(6):681-90
pubmed: 16091570
J Eur Acad Dermatol Venereol. 2016 Apr;30 Suppl 3:5-11
pubmed: 26995016
Epidemiol Rev. 1987;9:1-30
pubmed: 3678409
Int J Womens Dermatol. 2018 Nov 27;5(1):2-7
pubmed: 30809571
J Eur Acad Dermatol Venereol. 2008 Jan;22(1):65-72
pubmed: 18181975
Cancer Epidemiol. 2013 Apr;37(2):127-32
pubmed: 23295002
J Am Acad Dermatol. 2018 Mar;78(3):615-618.e2
pubmed: 28947292
J Invest Dermatol. 2013 Apr;133(4):913-8
pubmed: 23190883
J Natl Cancer Inst. 2011 Oct 5;103(19):1469-75
pubmed: 21878677
Am J Clin Dermatol. 2015 Feb;16(1):47-54
pubmed: 25516331
J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:13-27
pubmed: 30811698
Br J Dermatol. 2003 Jul;149(1):115-23
pubmed: 12890204
Stat Med. 2001 Feb 28;20(4):641-54
pubmed: 11223905
J Dermatol Sci. 2018 Oct;92(1):62-77
pubmed: 30104108
Prev Med. 2004 Jul;39(1):11-8
pubmed: 15207981
Int J Cancer. 2010 Nov 1;127(9):2190-8
pubmed: 20473901
Am J Med. 2010 May;123(5):439-45
pubmed: 20399321
Crit Rev Oncol Hematol. 2018 Feb;122:1-9
pubmed: 29458778
Int J Environ Res Public Health. 2010 Feb;7(2):427-42
pubmed: 20616983
BMC Public Health. 2019 Feb 18;19(1):206
pubmed: 30777037
Br J Dermatol. 2001 Mar;144(3):641-2
pubmed: 11260041
Cancer Causes Control. 2012 Feb;23(2):379-88
pubmed: 22215431
Eur J Dermatol. 2010 Nov-Dec;20(6):719-23
pubmed: 20923753
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-580.e9
pubmed: 28188769
Occup Environ Med. 2011 Dec;68(12):888-94
pubmed: 21486991
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):225-235
pubmed: 28573745
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
BMJ Open. 2014 May 02;4(5):e005137
pubmed: 24793258
Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1483-9
pubmed: 23833126
Stat Med. 2002 Feb 28;21(4):589-624
pubmed: 11836738
Contraception. 2013 Dec;88(6):678-83
pubmed: 24090961

Auteurs

Saverio Caini (S)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Via Cosimo il Vecchio 2, 50141, Florence, Italy. s.caini@ispro.toscana.it.

Simone Pietro De Angelis (SP)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Federica Corso (F)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Carolina Fantini (C)

Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Sara Raimondi (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Laura Pala (L)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Ignazio Stanganelli (I)

Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), IRCSS, Meldola, Italy.

Vincenzo de Giorgi (V)

Department of Dermatology, University of Florence, Florence, Italy.

Sara Gandini (S)

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH